- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05556343
En undersøgelse for at evaluere effektiviteten, sikkerheden og tolerabiliteten af MYK-224 hos deltagere med symptomatisk obstruktiv hypertrofisk kardiomyopati (MERCUTIO)
Et fase 2a, åbent, pilotstudie til evaluering af effektivitet, farmakokinetik, farmakodynamik, sikkerhed og tolerabilitet af MYK-224 hos deltagere med symptomatisk hypertrofisk kardiomyopati og obstruktion af venstre ventrikulær udløbskanal
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Local Institution - 0026
-
Los Angeles, California, Forenede Stater, 90048
- Local Institution - 0014
-
San Francisco, California, Forenede Stater, 94158-2156
- Local Institution - 0016
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66103-2937
- Local Institution - 0001
-
-
New York
-
New York, New York, Forenede Stater, 10032-3802
- Local Institution - 0032
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Local Institution - 0013
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- Local Institution - 0031
-
Cleveland, Ohio, Forenede Stater, 44195-0001
- Local Institution - 0015
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239-3011
- Local Institution - 0024
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37205-2202
- Local Institution - 0021
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78229-3900
- Local Institution - 0025
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84132
- Local Institution - 0006
-
-
-
-
-
Milan, Italien, 20138
- Local Institution - 0029
-
-
BO
-
Bologna, BO, Italien, 40138
- Local Institution - 0027
-
-
FI
-
Florence, FI, Italien, 50134
- Local Institution - 0005
-
-
-
-
-
Wroclaw, Polen, 54-049
- Local Institution - 0030
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polen, 40-555
- Local Institution - 0011
-
-
-
-
-
A Coruña, Spanien, 15006
- Local Institution - 0009
-
Barcelona, Spanien, 08036
- Local Institution - 0023
-
Majadahonda, Spanien, 28035
- Local Institution - 0010
-
-
A
-
Alicante, A, Spanien, 03010
- Local Institution - 0028
-
-
GR
-
Granada, GR, Spanien, 18014
- Local Institution - 0022
-
-
MA
-
Málaga, MA, Spanien, 29010
- Local Institution - 0008
-
-
MU
-
El Palmar, MU, Spanien, 30120
- Local Institution - 0002
-
-
V
-
Valencia, V, Spanien, 46026
- Local Institution - 0003
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier:
- Har tilstrækkelige akustiske vinduer til at muliggøre nøjagtige TTE'er som bestemt af ekkokardiografi-kernelaboratoriet.
Mænd eller kvinder diagnosticeret med oHCM i overensstemmelse med de nuværende retningslinjer fra American College of Cardiology Foundation/American Heart Association og European Society of Cardiology, der opfylder begge følgende kriterier:
- Har uforklarlig venstre ventrikel (LV) hypertrofi med ikke-udvidede ventrikulære kamre i fravær af anden hjertesygdom (f.eks. hypertension, aortastenose) eller systemisk sygdom og med maksimal LV vægtykkelse ≥ 15 millimeter (mm) (eller ≥ 13 mm med positiv familiehistorie af hypertrofisk kardiomyopati eller med en kendt sygdomsfremkaldende mutation), som bestemt ved kernelaboratoriefortolkning.
OG
-- Har en LVOT-topgradient under screening vurderet ved ekkokardiografi på ≥ 50 millimeter kviksølv (mm Hg) i hvile eller ≥ 30 mm Hg i hvile og ≥ 50 mm Hg efter Valsalva-manøvre (bekræftet ved ekkokardiografi kernelaboratoriefortolkning).
- Har dokumenteret LVEF ≥ 60 % ved screeningsbesøget som bestemt ved ekkokardiografi kernelaboratorium.
- New York Heart Association (NYHA) funktionelle klasse II eller III symptomer ved screening.
- Har en gyldig måling af LVOT-topgradient efter træning ved screening som bestemt af ekkokardiografi-kernelaboratorium.
Ekskluderingskriterier:
- Tilstedeværelse af enhver medicinsk tilstand, der udelukker træningsstresstest.
- Anamnese med synkope eller vedvarende ventrikulær takyarytmi inden for 6 måneder før screening.
- Kendt infiltrativ eller lagerlidelse, der forårsager hjertehypertrofi, der efterligner HCM, såsom Fabrys sygdom, amyloidose eller Noonans syndrom med venstre ventrikulær hypertrofi.
- Forudgående behandling med mavacamten eller aficamten. En undtagelse kan gøres i tilfælde, hvor brug af myosinhæmmere ikke fandt sted inden for 4 måneder efter screeningsbesøget, og med samtykke fra både investigator og sponsor Medical Monitor.
- Er blevet behandlet med succes med invasiv septal reduktion (kirurgisk myektomi eller perkutan alkohol septal ablation [ASA]) inden for 6 måneder før screening eller planlægger at få en af disse behandlinger under undersøgelsen (Bemærk: Personer med en mislykket myektomi eller perkutan ASA procedure udført > 6 måneder før screening kan tilmeldes, hvis undersøgelsesberettigelseskriterierne for LVOT-gradientkriterier er opfyldt).
- Implanterbar cardioverter-defibrillator (ICD) placering eller pulsgenerator ændring inden for 2 måneder før screening eller planlagt ny ICD placering under undersøgelsen (pulsgenerator ændringer, hvis nødvendigt under undersøgelsen er tilladt).
- Har en historie med genoplivet pludseligt hjertestop (når som helst) eller kendt historie med passende implanterbar cardioverter-defibrillator (ICD-udledning for livstruende ventrikulær arytmi inden for 6 måneder før screening.
- Har paroxysmal, intermitterende atrieflimren med atrieflimren til stede i henhold til investigatorens vurdering af deltagerens EKG på screeningstidspunktet.
- Har vedvarende eller permanent atrieflimren, der ikke er på antikoagulering i mindst 4 uger før screening og/eller ikke tilstrækkeligt frekvenskontrolleret inden for 6 måneder før screening (Bemærk: Deltagere med vedvarende eller permanent atrieflimren, som er antikoagulerede og tilstrækkeligt frekvenskontrollerede, er tilladt ).
- Har QT-interval med Fridericia-korrektion (QTcF) > 500 msek, når QRS-interval < 120 msek. eller QTcF > 520 msek., når QRS ≥ 120 msek., hvis deltageren har forladt grenblok eller enhver anden 12-aflednings-EKG-abnormitet, som en investigator vurderer at udgøre risiko for deltagernes sikkerhed (f.eks. andengrads atrioventrikulær blok type II).
- Har kendt moderat eller svær (efter investigator's vurdering) aortaklapstenose ved screening.
- Anamnese med LV systolisk dysfunktion (LVEF < 45 %) på et hvilket som helst tidspunkt under deres kliniske forløb.
- Har lungesygdom, der begrænser træningskapaciteten.
- Anamnese med obstruktiv koronararteriesygdom (stenose på > 70 % af luminal diameter i en eller flere kranspulsårer).
- Forudgående behandling med kardiotoksiske midler såsom antracykliner (f.eks. doxorubicin) eller lignende
Andre protokoldefinerede kriterier gælder.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Kohorte 1
Deltagerne vil modtage MYK-224 enten som monoterapi eller i kombination med standardbehandling bestående af en betablokker.
Deltagere, der gennemfører kohorte 1, vil være berettiget til en valgfri åben-label forlængelsesperiode
|
Specificeret dosis på specificerede dage
Andre navne:
|
|
Eksperimentel: Kohorte 2
Deltagerne vil modtage MYK-224 i kombination med standardbehandling bestående af enten en calciumkanalblokker eller disopyramid (som gives i kombination med enten en betablokker eller calciumkanalblokker).
Deltagere, der gennemfører kohorte 2, vil være berettiget til en valgfri åben-label forlængelsesperiode
|
Specificeret dosis på specificerede dage
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part A: Number of Participants With Adverse Events and Serious Adverse Events
Tidsramme: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization.
|
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Number of Participants With at Least One Event of Arrhythmias
Tidsramme: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
Arrhythmias included atrial fibrillation/flutter (new from screening and recurrent), ventricular tachyarrhythmias (ventricular tachycardia, ventricular fibrillation, and Torsades de Pointe).
|
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac Arrest
Tidsramme: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
|
Part A: Change From Baseline in Vital Signs - Heart Rate
Tidsramme: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
Heart rate was measured in rested state.
|
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Change From Baseline in Vital Signs - Mean Systolic Blood Pressure
Tidsramme: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
Systolic blood pressure was measured in rested state.
|
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Change From Baseline in Vital Signs - Mean Diastolic Blood Pressure
Tidsramme: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
Diastolic blood pressure was measured in rested state.
|
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Change From Baseline in Vital Signs - Respiratory Rate
Tidsramme: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
Respiratory rate was measured in rested state.
|
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Change From Baseline in Vital Signs - Temperature
Tidsramme: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
|
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Change From Baseline in Vital Signs - Weight
Tidsramme: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
|
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Number of Participants With Abnormal Physical Examination Results
Tidsramme: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
The complete physical examination included weight and calculated BMI, a neurological examination (gross motor and deep tendon reflexes),and an assessment of the following: general appearance, skin, head and neck, mouth, lymph nodes, thyroid, abdomen, musculoskeletal, cardiovascular, neurological, and respiratory systems with other systems included, as directed by interval history.
|
Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Results
Tidsramme: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Twelve-lead ECG evaluations will be performed in the supine position after 10 minutes of rest at Screening and at selected clinic visits prior to MYK-224 dosing and before any blood sample collection.
QTc prolongation is defined by either the mean of QTcF > 499 or mean of QTcB > 499 according to the project requirement specification from Clario.
|
Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Number of Participants With Adverse Events Related to Clinical Laboratory Parameters (Hematology, Chemistry and Urinalysis)
Tidsramme: Baseline and untill end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Blood samples were collected to assess the clinical laboratory parameters.
|
Baseline and untill end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50%
Tidsramme: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
LVEF was assessed using transthoracic echocardiogram (TTE) in resting state.
90% CIs are calculated based on Exact Binomial proportion test.
LVEF value was calculated by Simpson Biplane method.
|
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30%
Tidsramme: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
LVEF was assessed using transthoracic echocardiogram (TTE) in resting state.
90% CIs are calculated based on Exact Binomial proportion test.
LVEF value was calculated by Simpson Biplane method.
|
From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Part A: Aggregate Mean of Left Ventricular Ejection Fraction (LVEF)
Tidsramme: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
|
Part A: Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
Tidsramme: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
Participants with data available at the timepoint were included in the analysis.
|
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Aggregate Mean of Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)
Tidsramme: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
|
Part A: Change From Baseline in Left Ventricular Outflow Tract (LVOT) Peak Gradient (Post-Exercise, Resting, and Valsalva)
Tidsramme: Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
Participants with data available at the timepoint were included in the analysis.
|
Treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Percentage of Participants With Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient < 30 mmHg and Valsalva LVOT Peak Gradient < 50 mmHg
Tidsramme: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Baseline is defined as the last non-missing value in date/time recorded before the first dose of MYK-224.
90%CIs are calculated based on Normal approximation.
|
Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
|
Part A: Plasma Concentration of MYK-224
Tidsramme: Pre-dose and 1 hour post-dose end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Blood samples were collected to assess plasma concentration of MYK-224.
|
Pre-dose and 1 hour post-dose end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Bristol-Myers Squibb, Bristol-Myers Squibb
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CV029-009
- 2022-001292-14 (EudraCT nummer)
- U1111-1276-3555 (Registry Identifier: WHO)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .